The short version

From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.

  • Moderna is the larger company, worth $81.0B, about 2.0 times Revolution Medicines.
  • Moderna grew revenue faster over the last year (+2.1% vs -100.0%).

Side by side

The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.

MeasureMRNARVMD
Market cap$81.0B$39.6B
Share price$225.00$189.76
Revenue (last fiscal year)$1.9B$0
Free cash flow (last fiscal year)-$2.1B-$914M
Revenue growth, last year+2.1%-100.0%
Revenue growth per year, last 5 fiscal years-43.0%—
Operating margin-149.0%—
Net margin-141.4%—
Return on equity-46.6%-67.8%
P/E (trailing)——
Price / free cash flow——
EV / EBITDA——
FCF growth the price implies——
Dividend yield——
Debt / equity0.62x0.66x
Fundamental gradeFF
Superinvestors holding it25
Insider purchases, last 12 months20

Results from SEC filings

Revenue and free cash flow by fiscal year, from each company's 10-K filings.

Moderna

YearRevenueFree cash flowOp. margin
2021$18.5B$13.3B72.0%
2022$19.3B$4.6B48.9%
2023$6.8B-$3.8B-61.9%
2024$3.2B-$4.1B-121.9%
2025$1.9B-$2.1B-158.1%

Revolution Medicines

YearRevenueFree cash flowOp. margin
2021$29M-$154M-639.7%
2022$35M-$235M-730.0%
2023$12M-$358M-4207.1%
2024$0-$568M—
2025$0-$914M—

Where the revenue comes from

Moderna · by products, 2025

Net product sales$1.8B94%
Other revenue$126M6%

Revolution Medicines

No segment breakdown reported.

Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open MRNA in Investingly

Questions

Which is bigger, Moderna or Revolution Medicines?

Moderna (MRNA), at $81.0B against $39.6B.

Which grows faster, MRNA or RVMD?

Moderna: revenue grew +2.1% over the last year, against -100.0%.

Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.